Immune tweak shows promise for ALS in early trial

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * The patient has been correctly informed * The patient must have given his/her informed and signed consent. * The patient must be insured or beneficiary of a health insurance plan. * The patient is at least 18 years old and less than 75 years old * Probable, or laboratory-supported probable or definite ALS as defined by El Escorial Revised ALS diagnostic criteria (according to Airlie House Conference 1988) * Stable on riluzole treatment for more than 3 months with liver function test results \< 2ULN * Disease duration ≤ 5 years * Vital capacity ≥ 70% of normal * Ability to swallow without the requirement for nasogastric or PEG feeding * Agreement for patient to use an adequate method of contraception throughout the study and for 2 weeks after post study visit * The patient is available and willing to participate in seven study visits occurring at the CHU within the next six months Exclusion Criteria: * The patient is participating in another interventional study * Within the past three months, the patient has participated in another interventional * The patient is in an exclusion period determined by a previous study * The patient is under judicial protection * The patient is an adult under guardianship * The patient refuses to sign the consent * It is impossible to correctly inform the patient * Other life threatening disease * Presence of contra-indicated concomitant treatments or with potential neuroprotective benefit (see section 11.2 of the protocol) * Presence of tracheostomy or non-invasive ventilation * Use of Percutaneous endoscopic gastrostomy (PEG) or nasogastric tube * Presence of clinical infection (treated or untreated) * Positive serology for CMV, EBV (confirmed by viral load), or HIV * Vaccination within 8 weeks prior to first experimental dosing * Other disease precluding functional assessments * Cancer within the past 5 years (except stable non-metastatic basal cell skin carcinoma or in situ carcinoma of the cervix) * Severe cardiac or pulmonary disease * Documented auto-immune disorders except asymptomatic Hashimoto thyroiditis * Women of child bearing age without contraception or pregnant or breast feeding * Any clinically significant laboratory abnormality (excepting cholesterol, triglyceride and glucose)